Low-frequency repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation method that has been used in the treatments of stroke patients. Our purpose was to investigate the effects of low-frequency rTMS on the hand motor function recovery for stroke patients. After searching from electronic database from January 1990 to April 2012, we collected randomized controlled trials explored the low-frequency rTMS effects on the hand motor function rehabilitation. A total of 7 comparisons (N = 216) from 5 articles were included in this study. We summarized the effect size by calculating the standardized mean difference (SMD). Summary of effect size (SES) indicated positive effects of low-frequency rTMS on the finger motor ability (SMD = 0.58) and hand function (SMD = -0.98). Few adverse effects occurred. The evidence showed that low-frequency rTMS could improve the paretic hand recovery after stroke.
Hand ; physiopathology ; Humans ; Recovery of Function ; Stroke ; therapy ; Transcranial Magnetic Stimulation

Objective To analyze the differential protein expression of three negative breast cancer tissue before and after menopause application of iTRAQ technology, to explore the effects of menopause on three negative breast cancer. Methods Selected premenopausal and postmenopausal women with 8 cases in each by negative pathological diagnosis, differential protein analysis on significant function, difference of protein pathway and difference of protein verify were analyzed by the application iTRAQ technology. Results (1﹚Differential protein interactome was relatively centralized premenopausal, and postmenopausal differences of protein was much, and the distribution of the dispersed. (2﹚In pre menopausal cancer tissue protein differences existed in 5 of the significant difference in differences approach; post-menopausal cancer tissue protein existsed in 15 significantly different pathways. (3﹚Tumor adjacent tissues compared with premenopausal had a total of 214 significant difference proteins, postmenopausal had a total of 360 significant differ-ence proteins. The upregul ated proteins in 81 kinds of premenopausal three negative breast cancer tissues, 133 down regμl ated proteins, postmenopausal up-regμl ated protein 157 types, down 203. Conclusion Using iTRAQ technology to found that the expression has a certain particμl arity differences in three negative breast cancer before and after menopause, indicate three negative breast cancer may have different pathogenesis in the different estrogen environment, may be a new target for treatment of TNBC.

ObjectiveTo investigate the efficacy and safety of artificial liver support therapy with an Evanure-4A selective membrane plasma separator and its influence on platelet count in the treatment of patients with acute-on-chronic liver failure （ACLF） patients with different platelet counts. MethodsA total of 302 patients with ACLF who were hospitalized in Department of Hepatology， Chengdu Public Health Clinical Medical Center， from January 2021 to May 2023， were enrolled， and according to the platelet count （PLT）， they were divided into group A （25×10⁹/L — 50×10⁹/L） with 101 patients， group B （51×10⁹/L — 80×10⁹/L） with 98 patients， and group C （81×10⁹/L — 100×10⁹/L） with 103 patients. In addition to medical treatment， all patients received different modes of artificial liver support therapy based on their conditions， including plasma perfusion combined with plasma exchange， double plasma molecular adsorption combined with plasma exchange， and bilirubin system adsorption combined with plasma exchange. The paired t-test was used for comparison of continuous data before and after treatment in each group； an analysis of variance was used for comparison between multiple groups， and the SNK-q test was used for further comparison between two groups； the chi-square test was used for comparison of categorical data between multiple groups. ResultsOf all 302 patients， 268 （88.74%） achieved varying degrees of improvement in clinical symptoms after artificial liver support therapy. After treatment， all three groups had varying degrees of reductions in alanine aminotransferase （t=14.755， 21.614， and 15.965， all P<0.001）， aspartate aminotransferase （t=11.491， 19.301， and 13.919， all P<0.001）， total bilirubin （t=19.182， 17.486， and 21.75， all P<0.001）， and international normalized ratio （INR） （t=3.497， 3.327， and 4.358， all P<0.05）. After artificial liver support therapy with an Evanure-4A selective membrane plasma separator， PLT in group A decreased from （37.73±6.27）×10⁹/L before treatment to （36.59±7.96）×10⁹/L after treatment， PLT in group B decreased from （66.97±7.64）×10⁹/L before treatment to （62.59±7.37）×10⁹/L after treatment， and PLT in group C decreased from （93.82±5.38）×10⁹/L before treatment to （85.99±12.49）×10⁹/L after treatment； groups B and C had significant reductions in PLT after treatment （t=12.993 and 8.240， both P<0.001）， but there was no significant difference in group A （P>0.05）. There was no significant difference in the incidence rate of adverse reactions during artificial liver support therapy between the three groups （P>0.05）. ConclusionArtificial liver support therapy can improve liver function and INR in patients with ACLF. The use of Evaure-4A selective membrane plasma separator during artificial liver support therapy has little influence on platelets， and it is safe in the treatment of ACLF patients with a significantly lower level of platelets.